title: Serial clinical and angiographic follow-up after phosphorylcholine-coated stent implantation.
abstract: The efficacy of drug-eluting stents (DES) has been proven, but concerns about late complications after DES have been raised. Polymers that do not increase inflammatory or hypersensitivity reactions which may contribute to late complications are needed for new generation DES. To evaluate the safety and efficacy of phosphorylcholine-polymer coating, we investigated serial clinical and angiographic outcomes after phosphorylcholine-coated stent placement. Seventy-five consecutive patients treated with a BiodivYsio phosphorylcholine-coated stent for de novo lesions at our institute between October 2001 and August 2002 were enrolled. Six-month follow-up angiography was performed in 71 lesions (94.7%), and angiographic restenosis was found in 19 lesions (26.8%). Target lesion revascularization (TLR) was performed in 10 lesions (14.1%). Eighteen-month follow-up angiography was performed in 58 (95.1%) of the remaining 61 lesions (excluding TLR lesions), and angiographic restenosis was found in only 3 lesions. The cumulative MACE-free survival rate was 86.3%, 83.6%, and 78.6% at 6-month, 18-month, and 8-year follow-up, respectively. There were no episodes of stent thrombosis. Late loss decreased significantly from 0.74 ± 0.40 mm (6-months) to 0.51 ± 0.46 mm (18-months) (P < 0.0001). Phosphorylcholine-coated stent implantation was associated with acceptable clinical and angiographic results. Phosphorylcholine-coating may be an ideal polymer for new generation DESs.
authors.affiliation: Department of Cardiology, Kurashiki Central Hospital, Miwa, Kurashiki, Okayama, Japan.
authors.forename: Seiji
authors.initials: S
authors.lastname: Habara
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Mitsudo
authors.forename: Kazushige
authors.initials: K
authors.lastname: Kadota
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Goto
authors.forename: Satoki
authors.initials: S
authors.lastname: Fujii
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Harumi
authors.initials: H
authors.lastname: Katoh
authors.forename: Naoki
authors.initials: N
authors.lastname: Oka
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Fuku
authors.forename: Shingo
authors.initials: S
authors.lastname: Hosogi
authors.forename: Akitoshi
authors.initials: A
authors.lastname: Hirono
authors.forename: Takeshi
authors.initials: T
authors.lastname: Maruo
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Shigemoto
authors.forename: Daiji
authors.initials: D
authors.lastname: Hasegawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tasaka
authors.forename: Mana
authors.initials: M
authors.lastname: Kusunose
authors.forename: Suguru
authors.initials: S
authors.lastname: Otsuru
authors.forename: Yoji
authors.initials: Y
authors.lastname: Okamoto
authors.forename: Naoki
authors.initials: N
authors.lastname: Saito
authors.forename: Yuki
authors.initials: Y
authors.lastname: Tsujimoto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010767:Phosphorylcholine / Q000008:administration & dosage*
chemical_list: D010767:Phosphorylcholine